Cargando…

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors

HER2 targeted therapies have significantly improved prognosis of HER2-positive breast and gastric cancer. HER2 overexpression and mutation is the pathogenic driver in non-small cell lung cancer (NSCLC) and colorectal cancer, however, to date, there are no approved HER2-targeted therapies with these...

Descripción completa

Detalles Bibliográficos
Autores principales:	Indini, Alice, Rijavec, Erika, Grossi, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125530/ https://www.ncbi.nlm.nih.gov/pubmed/33946310 http://dx.doi.org/10.3390/ijms22094774

Ejemplares similares

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2023)

Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04
por: Zhan, Mei, et al.
Publicado: (2023)

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
por: Jerusalem, Guy, et al.
Publicado: (2022)

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
por: Indini, Alice, et al.
Publicado: (2021)

Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
por: Kotani, Daisuke, et al.
Publicado: (2021)

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors
por: Takahashi, Shunji, et al.
Publicado: (2021)

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
por: DiPeri, Timothy P., et al.
Publicado: (2023)

Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review
por: Indini, Alice, et al.
Publicado: (2021)

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
por: Antonarelli, G., et al.
Publicado: (2023)

Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan
por: Yin, Ophelia, et al.
Publicado: (2021)

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
por: Goto, Koichi, et al.
Publicado: (2023)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer
por: Shitara, Kohei, et al.
Publicado: (2021)

Trastuzumab deruxtecan for breast cancer
Publicado: (2022)

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
por: Mosele, Fernanda, et al.
Publicado: (2023)

Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review
por: Indini, Alice, et al.
Publicado: (2021)

Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
por: Vathiotis, Ioannis A., et al.
Publicado: (2023)

A Case of HER2 Mutated Colorectal Cancer Treated Successfully With Fam-Trastuzumab Deruxtecan
por: Reddy, Aswanth, et al.
Publicado: (2023)

Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
por: Alder, Laura, et al.
Publicado: (2023)

Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer
por: Shi, Demin, et al.
Publicado: (2023)

Novel treatment strategies for early-stage lung cancer: the oncologist’s perspective
por: Indini, Alice, et al.
Publicado: (2020)

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
por: Linehan, Anna S, et al.
Publicado: (2021)

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
por: Azar, Ibrahim, et al.
Publicado: (2021)

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib
por: Rijavec, Erika, et al.
Publicado: (2022)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2022)

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report
por: Riudavets, Mariona, et al.
Publicado: (2022)

Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer
por: Siddiqui, Tasmiyah, et al.
Publicado: (2022)

Correction: A Case of HER2 Mutated Colorectal Cancer Treated Successfully With Fam-Trastuzumab Deruxtecan
por: Reddy, Aswanth, et al.
Publicado: (2023)

Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel
por: Bianchini, Giampaolo, et al.
Publicado: (2022)

Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2‐Positive or HER2‐Low Metastatic/Unresectable Breast Cancer
por: Shimomura, Akihiko, et al.
Publicado: (2022)

Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States
por: Lang, Yitian, et al.
Publicado: (2022)

Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis
por: Matsui, Chiaki, et al.
Publicado: (2023)

Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
por: Rugo, H.S., et al.
Publicado: (2022)

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
por: Bartsch, Rupert, et al.
Publicado: (2022)

Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials
por: Xu, Hanyue, et al.
Publicado: (2022)

Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report
por: Ogata, Takatsugu, et al.
Publicado: (2022)

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
por: Pérez-García, José Manuel, et al.
Publicado: (2022)

Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy
por: Falk, Markus, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_93jpv6v6uldel86igrn4bkpd9o